Skip to main content

In potential $1.6 billion deal, Gilead snags yet another Bay Area cancer target

A complex option transaction got more complicated when Gilead's South San Francisco-based target had to create a spinout to deal with another deal signed last year.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.